tiprankstipranks
Stocks
Top Analyst Stocks
Popular
Top Smart Score Stocks
Popular
Top Insiders StocksMarket MoversTipRanks Momentum IndexDividend StocksAI StocksLargest Companies by Market Cap
ETFs
Top ETFs by UpsideTop ETFs by Smart ScoreTop Gainers/ Losers/ Active ETFs
Crypto
Bitcoin
Popular
Ethereum
Commodities
Gold
Options
Unusual Options Activity
Popular
Currency
EUR/USD
Research Tools
Trending StocksCompare StocksCompare ETFsMost Visited Websites
Daily Feeds
Daily Analyst RatingsDaily Insider Trading Tracker
Calendars
Earnings CalendarDividend CalendarEconomic CalendarIPO CalendarStock SplitsStock BuybacksMarket Holidays
Calculators
Dividend CalculatorDividend Yield CalculatorOptions Profit Calculator
Economic Indicators
Inflation RateUnemployment Rate
Class Actions
Stock ScreenerETF Screener
Popular
Penny Stock ScreenerTechnical Analysis Screener
Dividend CenterBest Dividend Stocks
Popular
Best High Yield Dividend StocksDividend AristocratsDividend Stock Comparison
New
Dividend CalculatorDividend Returns ComparisonDividend Calendar
My ExpertsTop AnalystsTop Financial BloggersTop-Performing Corporate InsidersTop Hedge Fund ManagersTop Research FirmsTop Individual Investors
Education
Personal FinanceHow To Use TipRanksTipRanks LabsWebinar CenterGlossaryFAQs
About Us
About TipRanksContact UsCareersReviewsMobile APP
Working with TipRanks
Enterprise SolutionsAdvertise with UsTop Online BrokersBecome an AffiliateTipRanks News WireArrivedEquityMultiple
Follow Us
TOOLS
Portfolio
Watchlist
Top Insiders Stocks
Popular
Top Stocks
Popular
Market Movers
Compare stocks
Compare ETFs
Notification Center
News
Stock Screener
ETF Screener
Popular
Penny Stock Screener
Technical Analysis Screener
Top Analyst Stocks
Popular
Top Smart Score Stocks
Popular
Top Insiders Stocks
Compare Stocks
Compare ETFs
Trending Stocks
Daily Analyst Ratings
Daily Insiders Trades
Dividend Stocks
ETF Center
Top Gainers/losers/active ETFs
Dividend Calculator
Options Profit Calculator
Dollar Cost Averaging
Earnings Calendar
Dividend Calendar
Economic Calendar
IPO Calendar
Stock Splits
Stock Buybacks
Market Holidays
Dividend Center
Best Dividend Stocks
Popular
Best High Yield Dividend Stocks
Dividend Aristocrats
Dividend Stock Comparison
New
Dividend Calculator
Dividend Returns Comparison
Dividend Calendar
Top Analysts
Top Financial Bloggers
Top-Performing Corporate Insiders
Top Hedge Fund Managers
Top Research Firms
Top Individual Investors
Top Gainers
Top Losers
Most Active
Premarket
After-hours
Personal Finance Center
Mortgages
Loans
Investing & Retirement
Spending & Savings
Real Estate
Top Online Brokers
Compound Interest Calculator
Mortgage Calculator
Auto Loan Calculator
Student Loan Calculator
401k Retirement Calculator
Enterprise Solutions
Plans & Pricing
Education
How To Use TipRanks
TipRanks Labs
Webinar Center
Glossary
FAQs
About Us
About TipRanks
Contact Us
Careers
Reviews
Mobile APP
Working with TipRanks
Enterprise Solutions
Top Online Brokers
Become an Affiliate
TipRanks News Wire
Follow Us
STOCKS
SPY
QQQ
AAPL
NVDA
TSLA
AMZN
BABA

Valneva’s Promising Growth and Strategic Positioning: Buy Rating Affirmed by Edward White
RatingsValneva’s Promising Growth and Strategic Positioning: Buy Rating Affirmed by Edward White
8d ago
VALN
Valneva price target lowered to $17 from $18 at H.C. Wainwright
PremiumThe Fly
Valneva price target lowered to $17 from $18 at H.C. Wainwright
8d ago
VALN
Valneva jumps 19% after chikungunya vaccine wins UK approval
PremiumThe Fly
Valneva jumps 19% after chikungunya vaccine wins UK approval
22d ago
VALN
MHRA grants Valneva marketing authorization for chikungunya vaccine
PremiumThe Fly
MHRA grants Valneva marketing authorization for chikungunya vaccine
22d ago
VALN
Valneva’s Vaccine Market Expansion and Revenue Growth Drives Buy Rating with $18 Price Target
PremiumRatings
Valneva’s Vaccine Market Expansion and Revenue Growth Drives Buy Rating with $18 Price Target
22d ago
VALN
Valneva reports Phase 2 results in children for its chikungunya vaccine
PremiumThe FlyValneva reports Phase 2 results in children for its chikungunya vaccine
1M ago
VALN
Valneva submits label extension application for chikungunya vaccine to FDA
Premium
The Fly
Valneva submits label extension application for chikungunya vaccine to FDA
3M ago
VALN
Valneva reports FDA Fast Track Designation for shigella vaccine candidate
Premium
The Fly
Valneva reports FDA Fast Track Designation for shigella vaccine candidate
4M ago
VALN
Valneva price target lowered to $20 from $23 at H.C. Wainwright
PremiumThe Fly
Valneva price target lowered to $20 from $23 at H.C. Wainwright
5M ago
VALN
Valneva price target lowered to $23 from $26 at H.C. Wainwright
PremiumThe Fly
Valneva price target lowered to $23 from $26 at H.C. Wainwright
5M ago
VALN
H.C. Wainwright positive on second booster results for VLA15
PremiumThe Fly
H.C. Wainwright positive on second booster results for VLA15
6M ago
PFE
VALN
Valneva, Pfizer say Phase 2 Lyme disease vaccine study positive
PremiumThe Fly
Valneva, Pfizer say Phase 2 Lyme disease vaccine study positive
6M ago
PFE
VALN
0OB3 Earnings Report this Week: Is It a Buy, Ahead of Earnings?
PremiumPre-Earnings0OB3 Earnings Report this Week: Is It a Buy, Ahead of Earnings?
7M ago
Pfizer, Valneva announce vaccination series completion in VALOR trial
Premium
The Fly
Pfizer, Valneva announce vaccination series completion in VALOR trial
8M ago
PFE
VALN
Valneva announces positive CHMP opinion for chikungunya vaccine
Premium
The Fly
Valneva announces positive CHMP opinion for chikungunya vaccine
9M ago
VALN
EMA recommends authorization for Valneva’s chikungunya vaccine
PremiumThe Fly
EMA recommends authorization for Valneva’s chikungunya vaccine
9M ago
VALN
Valneva price target lowered to $17 from $18 at Guggenheim
PremiumThe Fly
Valneva price target lowered to $17 from $18 at Guggenheim
11M ago
VALN
0OB3 Upcoming Earnings Report: What to Expect?
PremiumPre-Earnings
0OB3 Upcoming Earnings Report: What to Expect?
12M ago
Valneva sells Priority Review Voucher from FDA for $103M
PremiumThe Fly
Valneva sells Priority Review Voucher from FDA for $103M
1y ago
VALN
Valneva announces FDA approval of Ixciq
PremiumThe FlyValneva announces FDA approval of Ixciq
1y ago
VALN
Valneva announces FDA approval of Ixciq
Premium
The Fly
Valneva announces FDA approval of Ixciq
1y ago
VALN
Valneva price target raised to $26 from $22 at H.C. Wainwright
Premium
The Fly
Valneva price target raised to $26 from $22 at H.C. Wainwright
1y ago
VALN

Trending

Name
Price
Price Change
SPX
S&P 500
DJIA
Dow Jones
NDX
Nasdaq 100
More Trending Stocks >